02/10/2026
Alyftrek update: After Health Canada’s approval and a positive funding recommendation from Canada’s Drug Agency, Alyftrek is now with the pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug pricing on behalf of Canada’s public drug plans. In short: federal, provincial, and territorial drug plans can’t move forward until the pCPA process wraps up.
We’ve written to the pCPA, public drug plans and Vertex, the manufacturer of Alyftrek to stress the urgency of timely access. But more voices matter. Advocacy is critical to help ensure people living with cystic fibrosis can benefit from Alyftrek as soon as possible.
Are you interested in meeting with your provincial or territorial elected official to call for coverage of Alyftrek now? If so, please email advocacy@cysticfibrosis.ca with the subject line “Advocacy for Alyftrek”. A support package with key messages and materials will be provided to help guide the conversation.
Some private drug plans may already be covering Alyftrek. Please check with your plan provider to see if you are covered.
